Avatar

About Jane Barber

Dr Jane Barber PhD. Jane is an expereinced investigative and project toxicologist with expertise in cancer research, molecular toxicology and discovery project toxicology and has worked across multiple therapy areas including oncology. Jane has experience in evaluating the safety of drug targets and has extensive experience in mechanistic problem solving and in discovery project toxicology. Jane has a specialist expertise in hepatotoxicity, in vitro and in vivo problem solving, study design and reporting and has led global scientific strategy teams developing pre-clinical toxicity packages for mitigating the risk of transporter hepatotoxicity in discovery and development projects.

SOT 58th Annual Meeting & ToxExpo – 1663: Talk by Dr Jane Barber of ApconiX

At the Society of Toxicology 58th Annual Meeting and ToxExpo from March 10th to 14th at the Baltimore Convention Center, Dr Jane Barber of ApconiX will be giving a talk as part of the Safety Assessment: Pharmaceutical—Drug Discovery I Platform on Monday March 11th 1:45pm – 2:00pm in Convention Center Room 321. Target Safety Assessments: Evaluation of the Toxicological [...]

By |2019-02-28T16:43:08+00:00February 28th, 2019|Toxicology, Events|Comments Off on SOT 58th Annual Meeting & ToxExpo – 1663: Talk by Dr Jane Barber of ApconiX

Quantification of Drug-Induced Inhibition of Canalicular Cholyl-l-Lysyl-Fluorescein Excretion From Hepatocytes by High Content Cell Imaging.

Abstract We describe the use of a commercially available high content cell imaging algorithm (Cellomics Arrayscan Spot Detector) to quantify biliary excretion of the fluorescent probe substrate cholyl-l-lysyl-fluorescein (CLF) from rat hepatocytes cultured in collagen/matrigel sandwich configuration and to explore inhibition of this process by a variety of test compounds. The method provided robust, reproducible [...]

By |2018-09-26T14:04:32+01:00November 30th, 2015|Publications|Comments Off on Quantification of Drug-Induced Inhibition of Canalicular Cholyl-l-Lysyl-Fluorescein Excretion From Hepatocytes by High Content Cell Imaging.

In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.

Abstract Inhibition of the activity of the human bile salt export pump (BSEP: ABCB11) has been proposed to play a role in drug-induced liver injury (DILI). To enhance understanding of the relationship between BSEP inhibition and DILI, inhibition of human BSEP (hBSEP) and its rat ortholog (rBsep) by 85 pharmaceuticals was investigated in vitro. This [...]

By |2018-09-26T14:22:37+01:00January 31st, 2012|Publications|Comments Off on In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.